

Ref: FOI/GS/ID 6314

Please reply to: FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone, Kent ME16 9QQ Email: mtw-tr.foiadmin@nhs.net

15 December 2020

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Biologic drugs.

You asked:

Q1. Could you please provide the numbers of patients treated in the last 3 months by the **Dermatology** department (for any medical condition) with the following biologic drugs:

- · Adalimumab Humira
- · Adalimumab Biosimilar
- · Apremilast
- · Brodalumab
- · Certolizumab
- · Dimethyl fumarate
- · Etanercept Enbrel
- Etanercept Biosimilar
- · Guselkumab
- · Infliximab Remicade
- · Infliximab Biosimilar
- · Ixekizumab
- · Risankizumab
- · Secukinumab
- Tildrakizumab
- Ustekinumab

Q2. For the patients treated by the **Dermatology** department in the last three months with any of the above drugs, can you please provide the total number of paediatric (up to age 16) versus adult patients?

Q3. Could you please provide the numbers of patients treated in the last 3 months by the **Gastroenterology** department (for any medical condition) with the following biologic drugs:

a. Adalimumab - Humira

- b. Adalimumab Biosimilar
- c. Golimumab
- d. Infliximab Remicade
- e. Infliximab Biosimilar
- f. Tofacitinib
- g. Ustekinumab
- h. Vedolizumab

Trust response:

Q1. Maidstone and Tunbridge Wells NHS Trust does not provide dermatology services.

Q2. Not applicable

Q3.

- a. 23
- b. 141
- c. 1
- d. 0
- e. 140 f. 9
- g. 40
- h. 93